Related Experiment Video
Updated: Aug 12, 2025
03:23
Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
Published on: May 10, 2024
852
Treatment of primary eosinophilic colitis using immunoglobulin/histamine complex
Hyuk Soon Kim1,2, Geunwoong Noh3
1Department of Biomedical Sciences, College of Natural Science The Graduate School of Dong-A University Busan Korea.
Clinical Case Reports
|January 26, 2023
Summary
Immunoglobulin/histamine complex (IHC) shows promise for treating primary eosinophilic colitis (PEC). This therapeutic may alleviate pain associated with histamine in PEC patients.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Primary eosinophilic colitis (PEC) is a type of eosinophilic gastrointestinal disorder.
- Histamine plays a role in mediating pain in certain gastrointestinal conditions.
Observation:
- Immunoglobulin/histamine complex (IHC) has demonstrated a nonallergen-specific antinociceptive effect.
- This effect is relevant in the context of histamine-mediated pain.
Findings:
- IHC may serve as an effective therapeutic agent for primary eosinophilic colitis.
- The therapeutic potential of IHC lies in its ability to modulate histamine-related pain pathways.
Implications:
- Further research into IHC could lead to novel treatment strategies for PEC.
- Understanding IHC's mechanism may advance the management of eosinophilic gastrointestinal disorders.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
212
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
212
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
391
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
391
01:21Drugs for Treatment of Constipation-Predominant IBS
275
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
275
01:17Drugs for Treatment of Diarrhea-Predominant IBS
256
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
256
01:29Inflammatory Bowel Disease IV: Pharmacological Management
169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
169
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
181
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
181